AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

Why It Matters

The data confirm DCBs as a viable, less invasive alternative to repeat stenting for high‑risk ISR patients, reshaping treatment algorithms and influencing reimbursement and guideline discussions.

Key Takeaways

• 3‑year TLF 32.7% DCB vs 40.9% balloon.
• Benefit driven by lower TLR and target‑vessel MI.
• Adoption reached 12,729 US cases, 18% ISR market.
• Off‑label DCB use 27% despite limited evidence.
• Stent thrombosis 0.3% DCB vs 3.8% balloon.

Pulse Analysis

The AGENT IDE three‑year results reinforce the therapeutic niche of drug‑coated balloons in a patient cohort traditionally managed with repeat stenting. By halving the hazard of target‑lesion failure compared with plain balloon angioplasty, the DCB demonstrates a clear clinical edge, especially in reducing repeat revascularization and target‑vessel myocardial infarction. While the benefit plateaus after the first year, the early advantage is critical for patients who have already endured multiple drug‑eluting stents, a group at heightened risk for procedural complications and poor long‑term outcomes.

Beyond efficacy, the real‑world adoption of the Agent DCB has accelerated since FDA clearance. Over 12,700 procedures were logged in the CathPCI Registry within just a year, propelling the device to 18% of all ISR interventions. Hospital uptake varies markedly, with 41% of centers stocking the balloon by mid‑2025, reflecting both enthusiasm and lingering uncertainty. Notably, off‑label applications now represent a quarter of DCB use, highlighting clinicians’ perception of an unmet need in de‑novo lesions despite the absence of robust trial data and pending reimbursement pathways.

For interventional cardiology, these findings prompt a reassessment of ISR management strategies. The lower stent thrombosis rate and comparable safety profile suggest DCBs could become the default option when repeat stenting is undesirable. However, the persistent 30%+ three‑year TLF underscores the necessity for continued innovation, whether through next‑generation coatings or hybrid approaches. Ongoing registries and prospective trials will be pivotal in defining long‑term durability, informing guideline updates, and clarifying the role of DCBs in off‑label settings, ultimately shaping the future landscape of coronary revascularization.